Autobahn Therapeutics, Inc.
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/
Autobahn Therapeutics, Inc. is a biotechnology research company headquartered in San Diego, California, United States. The team counts 34 people, up 6% over the last year. Autobahn Therapeutics, Inc. has a website drawing 3K monthly visits and most of the team based in USA.
Employee growth
Autobahn Therapeutics, Inc. grew from ~28 employees in November 2022 to 27 by October 2024, reaching 34 by September 2026, tracked weekly in Crustdata's proprietary dataset since November 2022.
Investors
Autobahn Therapeutics, Inc.'s 16 backers include leading firms such as ARCH Venture Partners, Alexandria Venture Investments, Biogen, and Biotechnology Value Fund.
Leadership
Autobahn Therapeutics, Inc.'s leadership includes Chairman and CEO Kevin Finney, Chief Scientific Officer Jason Harris, Chief Business Officer Will Stratton, and EVP, Head of Research and Development, CMO Gudarz Davar.
Industries & markets
Autobahn Therapeutics, Inc. is classified across the following industries, categories, and markets that Crustdata tracks for competitive analysis and sector benchmarking.
See the top Biotechnology Research companies ranked by size, growth and funding.
In the news
Autobahn Therapeutics, Inc. has been featured in recent press coverage that Crustdata tracks to surface signals on launches, fundraising, partnerships, and other newsworthy events.
- Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons
- Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects
- Autobahn Therapeutics’ Elunetirom Receives FDA Fast Track Designation for Bipolar Disorder Treatment
- Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Autobahn Therapeutics, Inc. Growth Score
Autobahn Therapeutics, Inc. has a Crustdata Growth Score of 38 out of 100, which points to steady growth. Behind the number: headcount grew 6% year over year, web traffic grew 42% quarter over quarter, and it last raised funding 27 months ago.
Autobahn Therapeutics, Inc. FAQs
Below are 9 of the most common questions about Autobahn Therapeutics, Inc., answered with data tracked and refreshed weekly using Crustdata's proprietary dataset.